Loading…
SpyGlass Pharma, Inc. is projected to decline to $19.21 by 2027, a -5% move from its current price of $20.17. SGP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $19.56 | $20.15 | $20.77 | -0.08% |
| May 30 | $19.30 | $20.14 | $21.01 | -0.15% |
| May 31 | $19.10 | $20.12 | $21.20 | -0.23% |
| Jun 1 | $18.94 | $20.11 | $21.35 | -0.30% |
| Jun 2 | $18.79 | $20.09 | $21.49 | -0.38% |
| Jun 3 | $18.65 | $20.08 | $21.61 | -0.46% |
| Jun 4 | $18.53 | $20.06 | $21.72 | -0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.53 | $20.06 | $21.72 | -0.53% |
| Week 2 | $17.83 | $19.96 | $22.33 | -1.06% |
| Week 3 | $17.30 | $19.85 | $22.78 | -1.59% |
| Week 4 | $16.84 | $19.74 | $23.15 | -2.11% |
| Week 5 | $16.44 | $19.64 | $23.46 | -2.63% |
| Week 6 | $16.08 | $19.53 | $23.74 | -3.15% |
| Week 7 | $15.74 | $19.43 | $23.98 | -3.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SpyGlass Pharma, Inc. (SGP) is a Healthcare focused biopharmaceutical company that develops treatment and drug delivery solutions for patients with chronic eye conditions. It designs the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which uses novel drug pads attached to an intraocular lens (IOL) to be implanted during routine cataract surgery with the aim of reducing elevated intraocular pressure (IOP).
The company also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The business originated in 2019 and is based in Aliso Viejo, California.
SpyGlass Pharma, Inc. trades under the symbol SGP and operates in the Healthcare sector. The current price is $20.84, with a market capitalization of $696.75M and a rank of 2784. These figures establish the stock’s current standing in the market framework.
The overall price outlook shows mixed near-term signals, with the 2026 forecast at an average of $20.84 and a neutral sentiment, followed by a sequence of years with varying outcomes through 2029. From 2030 onward, the forecast turns increasingly bullish, culminating in substantial upside by 2050, though with notable year-to-year variability.
A major floor 17.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 25.9% above — a clean break opens room to run.
A major ceiling 47.1% above — clearing it would confirm fresh momentum.
Key SGP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SGP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.11 | Sell | $20.99 | Sell |
| MA 10 | $22.03 | Sell | $21.75 | Sell |
| MA 20 | $23.00 | Sell | $22.55 | Sell |
| MA 50 | $23.66 | Sell | $23.70 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.19 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -146.18 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.34 | Sell |
| ROC (12) | -13.84 | Sell |
| Bollinger %B (20,2) | 0.03 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -2.19 | Sell |
| Ultimate (7,14,28) | 22.21 | Buy |
| Momentum (10) | -3.97 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 20.32 | Sell |
| ADX (14) | 14.46 | Neutral |
| ATR (14) | 0.66 | Info |
The 30-day technical picture places SpyGlass Pharma in a cautious zone. The sentiment is BEARISH, with RSI14 at 40 and the 50-day simple moving average (SMA50) at $23.92. The price currently sits near support at $20.84 and faces resistance at $25.39, with a 30-day range spanning $16.90 to $25.70.
Annualized volatility is high at 60%, underscoring elevated short-term price swings. Traders may expect continued fluctuations within the near-term range, with potential tests of the support and resistance levels as market dynamics evolve.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $20.17 | $20.17 | $26.75 | 0% | Neutral | |
| $14.28 | $19.21 | $27.86 | -5% | Neutral | |
| $13.34 | $18.84 | $28.82 | -7% | Neutral | |
| $12.73 | $18.74 | $29.91 | -7% | Neutral | |
| $14.19 | $21.68 | $35.83 | +7% | Neutral | |
| $15.57 | $24.63 | $41.96 | +22% | Bullish | |
| $15.56 | $25.44 | $44.53 | +26% | Bullish | |
| $15.45 | $26.05 | $46.72 | +29% | Bullish | |
| $14.60 | $25.38 | $46.54 | +26% | Bullish | |
| $14.62 | $26.17 | $48.99 | +30% | Bullish | |
| $16.74 | $34.46 | $70.22 | +71% | Bullish | |
| $29.19 | $64.87 | $149.16 | +222% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $20.17 | $20.17 | $23.80 | +0.00% |
| June 2026 | $16.17 | $19.26 | $23.69 | -4.49% |
| July 2026 | $15.57 | $18.82 | $23.65 | -2.33% |
| August 2026 | $15.73 | $19.21 | $24.55 | +2.11% |
| September 2026 | $15.53 | $19.15 | $24.80 | -0.31% |
| October 2026 | $15.11 | $18.79 | $24.63 | -1.88% |
| November 2026 | $15.41 | $19.31 | $25.57 | +2.75% |
| December 2026 | $15.85 | $20.00 | $26.75 | +3.58% |
Click any year to see its month-by-month SGP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SGP price prediction for 2026 points to an average of $20.17 (low $20.17, high $26.75) — a potential gain of 0% on today's $20.17. A consolidation phase looks the most probable path here.
In 2027, SGP is projected to trade between $14.28 and $27.86, averaging $19.21 — a potential decline of -5% from today's $20.17. That is -5% versus the projected 2026 average. Price action looks broadly range-bound.
SpyGlass Pharma, Inc.'s 2028 outlook centres on $18.84, within a $13.34 to $28.82 range. That is -2% versus the projected 2027 average. That marks a -7% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, SGP could reach as high as $29.91, with a base case around $18.74 and support toward $12.73 — roughly -7% from $20.17. Price action looks broadly range-bound.
Expect SGP to range from $14.19 to $35.83 through 2030. The $21.68 average target implies a +7% move from current prices. That is up +16% on the projected 2029 average. A consolidation phase looks the most probable path here.
The SGP price prediction for 2031 points to an average of $24.63 (low $15.57, high $41.96) — a potential gain of +22% on today's $20.17. Momentum favours further upside here.
In 2032, SGP is projected to trade between $15.56 and $44.53, averaging $25.44 — a potential gain of +26% from today's $20.17. That is up +3% on the projected 2031 average. Buyers look set to stay in control over this stretch.
SpyGlass Pharma, Inc.'s 2033 outlook centres on $26.05, within a $15.45 to $46.72 range. That is up +2% on the projected 2032 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2034, SGP could reach as high as $46.54, with a base case around $25.38 and support toward $14.60 — roughly +26% from $20.17. Buyers look set to stay in control over this stretch.
Expect SGP to range from $14.62 to $48.99 through 2035. The $26.17 average target implies a +30% move from current prices. That is up +3% on the projected 2034 average. Momentum favours further upside here.
The SGP price prediction for 2040 points to an average of $34.46 (low $16.74, high $70.22) — a potential gain of +71% on today's $20.17. Buyers look set to stay in control over this stretch.
In 2050, SGP is projected to trade between $29.19 and $149.16, averaging $64.87 — a potential gain of +222% from today's $20.17. That is up +88% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SGP today (≈ 49.578582 SGP) could be worth
$3,215.96
+$2,215.96 (+222%) by 2050 · US Dollar
Based on the average projected SGP price of $64.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SGPwould be worth at today's price.
$1,000 invested in SGP on Feb 6, 2026 (≈ 37.878788 SGP) would be worth
$764.02
-$235.98 (-23.6%) today · 0.76× · US Dollar
Based on a SGP entry price of $26.4 vs. today's $20.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.89 | $921.43 | -7.9% |
| 1 month ago | $23.65 | $852.85 | -14.7% |
| 3 months ago | $28.35 | $711.46 | -28.9% |
| All time ago | $26.4 | $764.02 | -23.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SGP forecast.
Our base-case forecast reaches $40.00 around 2050.
Implied market cap at $40.00: $1.34B
The multi-year forecast shows a clear upward trajectory after the near-term period. In 2026 the average price is $20.84 with a 0% ROI and a neutral sentiment, followed by softer averages in 2027 ($19.70) and 2028 ($19.63) with negative ROIs of -5.5% and -5.8%, respectively. The 2029 forecast also remains neutral with an average of $19.54 and a -6.2% ROI.
From 2030 onward, average prices rise: 2030 $22.89 (ROI 9.8%), 2031 $26.33 (ROI 26.4%), 2032 $26.87 (ROI 28.9%), 2033 $27.53 (ROI 32.1%), 2034 $27.04 (ROI 29.8%), and 2035 $27.60 (ROI 32.4%). The bullish trend strengthens into 2040 with an average of $36.93 (ROI 77.2%) and continues to 2050 at an average of $70.89 (ROI 240.2%), with a maximum projected price of $38.49 in 2030, $77.14 in 2040, and $163.06 in 2050.
These figures illustrate substantial long-term upside potential alongside near-term caution. These are estimates, not guarantees, and should not be construed as financial advice.
Tap a question to reveal the answer.
2030 avg $22.89; min $14.69; max $38.49; ROI 9.8; sentiment NEUTRAL.
Near-term forecast shows 2026 avg $20.84 with ROI 0 and NEUTRAL sentiment; 2027 avg $19.70 with ROI -5.5; 2028 avg $19.63 with ROI -5.8; 2029 avg $19.54 with ROI -6.2.
Yes, the 2050 max is $163.06, with a 2040 max of $77.14, indicating that a $100 level is within the modeled path by 2050.
Sentiment BEARISH; RSI14 40; SMA50 $23.92; support $20.84; resistance $25.39; 30-day range $16.90-$25.70; annualized volatility 60%.
Market cap $696.75M; rank 2784.
SpyGlass Pharma, Inc. Community Discussion
0Share your SpyGlass Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.